Press Releases
  Date Title and Summary View
Apr 19, 2016
ROCKVILLE, Maryland, April 19, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the presentation of ...
Apr 6, 2016
Rockville, MD, April 06, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Jon Wiggin...
Mar 16, 2016
ROCKVILLE, Maryland, March 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced t...
Mar 7, 2016
MGD009 is a bispecific DART molecule that targets B7-H3 and CD3 Redirected T-cell killing of multiple B7-H3-expressing tumor cell lines observed in vitro Dose-dependent inhibition of tumor growth and regression observed in vivo Linear PK and prolonged h...
Feb 29, 2016
Eight molecules in clinical development, including six in immuno-oncology Multi-national Phase 1b/2 gastric cancer study initiated evaluating the combination of margetuximab and pembrolizumab Strong balance sheet supports continued advancement of p...
Feb 16, 2016
ROCKVILLE, Md., Feb. 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that on Monday,...
Feb 4, 2016
Rockville, Md., Feb. 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koen...
Dec 2, 2015
ROCKVILLE, Md., Dec. 02, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D....
Nov 7, 2015
Anti-B7-H3 antibody is well-tolerated Single-agent, anti-tumor activity observed across several tumor typesInitial evidence of T-cell immunomodulatory role ROCKVILLE, Md., Nov. 07, 2015 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal an...
Nov 5, 2015
Second paper published demonstrating DART molecule potential against HIVData support HIV research contract recently awarded to MacroGenics by NIAID ROCKVILLE, Md., Nov. 05, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal anti...
Nov 4, 2015
Bi-specific antibody leadership — fifth DART® molecule (MGD009) enters clinical testingB7-H3 franchise advances — Encouraging initial clinical results from ongoing enoblituzumab (MGA271) Phase 1 trial and regional rights regained ...
Nov 4, 2015
ROCKVILLE, Md., Nov. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D....
Oct 28, 2015
Rockville, MD, Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 4, 2015, the Company will release its financial results for the quarter ended September 30, 2015. The Company's management team will host a conference call discussing the Company's financial results and recent corporate de...
Oct 28, 2015
Server does not exercise option to license rights for enoblituzumab in its specified territoriesMacroGenics advances enoblituzumab and pursues integrated B7-H3 franchise strategy Rockville, MD, Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing i...
Oct 22, 2015
ROCKVILLE, MD and KENILWORTH, NJ , Oct. 22, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases, and Merck (NYSE: MRK), ...
Oct 13, 2015
Encouraging initial clinical results from ongoing enoblituzumab (MGA271) trialB7-H3 franchise extended — fifth DART® molecule (MGD009) in Phase 1Proprietary immune checkpoint PD-1 x LAG-3 DART molecule (MGD013) introducedHIV DART and Trident™ tri-specific platform introduced ROCKVILLE, Md., Oct. 13, 2015 (GLOBE NEWSWIRE) -...
Oct 6, 2015
ROCKVILLE, Md., Oct. 06, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that it will host a live webcas...
Oct 1, 2015
ROCKVILLE, Maryland, Oct. 01, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that interim res...
Sep 22, 2015
ROCKVILLE, Md., Sept. 22, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D....
Sep 3, 2015
ROCKVILLE, Md., Sept. 03, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that its senior management w...
Aug 5, 2015
-- Fourth bi-specific DART® molecule, MGD011, in clinical testing         -- Margetuximab Phase 3 SOPHIA metastatic breast cancer study initiated        -- Balance sheet strengthened with completion of $141 million equity offering ROCKVILLE, Md., Aug. 05, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biop...
Aug 4, 2015
Rockville, MD, Aug. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., ...
Jul 29, 2015
ROCKVILLE, Md, July 29, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 5, 2015, the Company will release its financial results for the quarter ended June 30, 2015. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developme...
Jul 28, 2015
— Triggers $10 million milestone payment from Janssen  — Fourth DART® molecule to enter the clinic in last 12 months ROCKVILLE, Md., July 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therape...
Jul 14, 2015
ROCKVILLE, Md., July 14, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, announced the pricing of an underwritten public of...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close